Multicentre early experience with totally subcutaneous cardioverter-defibrillators in Poland

Krzysztof Kaczmarek(Medical University of Lodz), Paweł Ptaszyński(Medical University of Lodz), Michał Kowara, Maciej Kempa(Gdańsk Medical University), Radosław Zwoliński, Mariusz Gąsior(Silesian Center for Heart Disease), Szymon Budrejko(Gdańsk Medical University), Grzegorz Opolski(Medical University of Warsaw), Marcin Grabowski, Marcin Michalak(Medical University of Silesia), Adam Sokal(Silesian Center for Heart Disease), Grzegorz Raczak(Gdańsk Medical University), Mateusz Tajstra(Silesian Center for Heart Disease), Iwona Cygankiewicz(Medical University of Lodz), Anna Kurek(Medical University of Silesia), Jerzy Krzysztof Wranicz(Medical University of Lodz), Oskar Kowalski(Silesian Center for Heart Disease)
Archives of Medical Science
June 6, 2019
10.5114/aoms.2019.83817
Cited by 5

Related Papers

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
|The Lancet|2017|588
Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|European Heart Journal|2018|285
Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension
|JAMA|2020|232
Prospective, multicenter validation of a clinical risk score for left atrial arrhythmogenic substrate based on voltage analysis: DR-FLASH score
|Heart Rhythm|2015|202